Search Clinical Trials in the European Union

Duration
Visits
Phase
Oral
Benefits
Drugs
Locations
Clinical Specialty
1261-1280 of 1,694 trials

MELAS: Testing Zagociguat

We are studying the investigational drug zagociguat to see if it helps reduce fatigue and improve thinking skills in people with MELAS. The trial also looks at its safety and effects on muscle weakness and memory.

MELAS Syndrome6-12 monthsEfficacy phase (II)6-10 visitsPost-Trial Drug AccessInvestigational MedicinesPartially RemoteInternal MedicineNeurology

ADHD and Depression: Dexamfetamine Formulations Study

We are investigating the safety and effectiveness of two dexamfetamine sulfate formulations for adults with ADHD and moderate to severe depression. This study aims to see how these treatments compare to a placebo in improving symptoms and managing side effects.

Major DepressionAttention Deficit Hyperactivity Disorder (ADHD)3-6 monthsEfficacy phase (II)≤5 visitsInvestigational MedicinesPsychiatry

Chronic Myeloid Leukemia: Second Stop of TKI Treatment

We are studying whether patients with CML can maintain remission after stopping their medication for a second time. This trial aims to identify factors that may help in achieving better treatment outcomes.

Chronic Myeloid Leukemia>2 yearsEfficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesHematologyOncology

Rett Syndrome: Testing Mirtazapine

We are studying whether Mirtazapine can improve social behavior, anxiety, and sleep quality in patients with Rett syndrome. This research may help us understand how to better manage symptoms of this condition.

Rett Syndrome6-12 monthsEfficacy phase (II)6-10 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesPartially RemoteNeurologyPsychiatry

Mucositis in Metastatic Renal Cell Carcinoma: Folic Acid Supplement Study

We are studying whether a folic acid supplement can help reduce mucositis in patients with metastatic renal cell carcinoma receiving targeted therapy. This trial will also assess the impact on quality of life and treatment side effects.

Metastatic Renal Cell Carcinoma≤3 monthsEfficacy phase (II)≤5 visitsStandard MedicinesInternal MedicineOncology

HIV-1 Control: Genetic and Immune Response Study

We are studying early-treated HIV-1 patients who stopped their antiretroviral therapy to find out if specific genetic and immune markers can predict their ability to control the virus. This research may help improve future treatment strategies.

HIV Positive During Acute Phase>2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesInfectious Diseases

Erectile Rehabilitation with Sildenafil After Rectal Cancer Surgery

We are studying whether Sildenafil can help men maintain erectile function after proctectomy for rectal cancer. This trial will evaluate its effects on sexual health and quality of life over the year following surgery.

Men Treated with Proctectomy for Rectal Cancer>2 yearsConfirmation phase (III)≤5 visitsInvestigational MedicinesCost ReimbursementOncologyUrology

Gastrointestinal Stromal Tumor: Adjuvant Imatinib Study

We are studying whether adjuvant Imatinib can help prevent cancer recurrence in patients with intermediate-risk gastrointestinal stromal tumors. This trial compares its effects on survival and quality of life against standard treatments.

Gastrointestinal Stromal Tumor>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesGastroenterologyOncology

Aggressive Multiple Sclerosis: Stem Cell Transplant Study

We are investigating whether stem cell transplantation can prevent disease activity in people with aggressive multiple sclerosis. The study will also monitor safety and other health changes over time.

Relapsing-Remitting Multiple Sclerosis>2 yearsEfficacy phase (II)16-20 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesHematologyNeurology

Preventing Heart Issues in Cancer Patients: Empagliflozin Study

We are studying whether empagliflozin can help prevent heart problems in cancer patients undergoing chemotherapy with anthracyclines. We will compare its effects to a placebo to assess safety and effectiveness.

Cardiotoxicity1-2 yearsConfirmation phase (III)≤5 visitsStandard MedicinesPartially RemoteCardiologyOncology

Osteogenesis Imperfecta: Losartan Therapy Study

We are investigating the right dose of losartan for older adolescents and adults with Osteogenesis Imperfecta. The study aims to see how it affects bone health and quality of life.

Brittle Bone Disease3-6 monthsEfficacy phase (II)No PlaceboStandard MedicinesCost ReimbursementPartially RemoteInternal MedicineOrthopedics and Traumatology

Diffuse Large B-Cell Lymphoma: Zilovertamab Vedotin with R-CHP

We are studying a new treatment combining zilovertamab vedotin with standard therapy for people with diffuse large B-cell lymphoma. The goal is to see if this combination works better than another treatment option.

Diffuse Large B-Cell Lymphoma>2 yearsEfficacy phase (II)Investigational MedicinesCost ReimbursementPartially RemoteHematologyOncology

Gout Treatment: Immediate vs. Delayed Febuxostat

We are studying whether starting febuxostat right after a gout attack helps reduce the number of gout days compared to starting it six weeks later. This trial is for individuals experiencing acute gout attacks.

Gout>2 yearsConfirmation phase (III)≤5 visitsNo PlaceboStandard MedicinesOrthopedics and TraumatologyRheumatology

CRD-4730 for Catecholaminergic Polymorphic Ventricular Tachycardia

We are studying a new medication, CRD-4730, to see if it is safe and tolerable for people with CPVT. The trial will also assess its effects on heart rhythm during exercise.

Catecholaminergic Polymorphic Ventricular TachycardiaEfficacy phase (II)Investigational MedicinesPartially RemoteCardiologyHematologyInternal Medicine

Kidney Transplant: Belatacept vs. Anticalcineurins

We are studying whether switching from anticalcineurins to Belatacept improves blood vessel function and reduces arterial stiffness in kidney transplant patients. This may help enhance overall cardiovascular health.

Kidney Transplant>2 yearsMonitoring phase (IV)Post-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementNephrology

Hydroxychloroquine for Recurrent Pregnancy Loss

We are studying whether Hydroxychloroquine can help women with recurrent pregnancy loss achieve a live birth. The trial also examines pregnancy outcomes and potential complications compared to a placebo.

Recurrent Pregnancy Loss6-12 monthsEfficacy phase (II)Standard MedicinesGynecology and Obstetrics

IVF Success: Exercise and Mediterranean Diet vs. Aspirin

We are studying whether exercise and a Mediterranean diet can improve live birth rates compared to aspirin for women undergoing in vitro fertilization. This research aims to find better ways to support fertility.

Women's Infertility>2 yearsConfirmation phase (III)6-10 visitsStandard MedicinesPartially RemoteCardiologyGynecology and Obstetrics

Mantle Cell Lymphoma: Sonrotoclax Plus Zanubrutinib

We are investigating whether the combination of sonrotoclax and zanubrutinib is more effective than a placebo with zanubrutinib for adults with relapsed or refractory mantle cell lymphoma. The study will also look at safety and how patients feel during treatment.

Relapsed or Refractory Mantle Cell LymphomaConfirmation phase (III)Investigational MedicinesOncology

Chronic Spontaneous Urticaria and Hidradenitis Suppurativa: INF904 Study

We are evaluating the safety of an oral medication called INF904 for people with moderate to severe chronic spontaneous urticaria or hidradenitis suppurativa. This study will help us understand how the medication works in the body.

Chronic Spontaneous UrticariaHidradenitis Suppurativa≤3 monthsEfficacy phase (II)6-10 visitsNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteAllergologyDermatology

Medulloblastoma Treatment: MEMMAT Trial

We are studying a combination of anti-cancer drugs for children with recurrent brain tumors. The goal is to see if this treatment improves response rates and overall survival.

Rare CNS Tumors≤3 monthsEfficacy phase (II)No PlaceboInvestigational MedicinesNeurologyOncology